Cardiovascular Update: Renal Denervation Endorsed, Repatha Label Expands, 3D Heart Patch and More
From cutting-edge trials to global regulatory wins, this month’s cardiovascular roundup delivers the most critical updates shaping the future of heart health. Whether you’re a clinician, researcher, or healthcare strategist, this video brings you the insights that matter most.
📌 In This Episode:
🇺🇸 U.S. Hypertension Guidelines now recommend renal denervation as a Class IIb treatment option, with CMS coverage expected soon.
🧩 ETH Zurich debuts a 3D-printed biodegradable heart patch with rapid tissue integration and bleeding control.
🛡️ Cardiovascular devices dominate the FDA’s Breakthrough Device program—leading all other specialties in innovation.
🧬 New biomarkers significantly enhance stroke risk prediction in atrial fibrillation, backed by 12-year cohort data.
💉 AGENT DCB global trial by Boston Scientific targets complex coronary lesions with stent-free treatment potential.
🌫️ HEPA air filters reduce systolic BP by 3 mmHg in pollution-exposed individuals—highlighting environment’s role in CV health.
🌍 Merck announces major data reveals at ESC 2025 on ASCVD, PAH, and HFrEF, featuring WINREVAIR and VERQUVO.
📈 FDA expands Repatha’s label for broader use in high-risk populations, including monotherapy for HoFH.
💓 AVIM therapy reduces systolic BP by up to 19 mmHg in hypertensive pacemaker patients.
🇯🇵 Japan approves the Paradise Renal Denervation System, marking a major regulatory milestone post U.S. and EU launches.
📢 Stay Ahead in Cardiovascular Research!
✅ Like, share, and subscribe for weekly updates on cardiovascular innovation
#Cardiology #Hypertension #StrokePrevention #HeartHealth #FDAUpdates #ClinicalTrials #Repatha #RenalDenervation #ESC2025 #CardiovascularInnovation #BiotechNews #DigitalHealth #MedTech